Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,985,127 papers from all fields of science
Search
Sign In
Create Free Account
amrubicin
Known as:
(+)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)- 6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione
A synthetic 9-amino-anthracycline with antineoplastic activity. Amrubicin intercalates into DNA and inhibits the activity of topoisomerase II…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
5 relations
Broader (2)
Anthracyclines
Antineoplastic Agents
NCIt Antineoplastic Agent Terminology
Narrower (2)
SM 5887
amrubicin hydrochloride
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
[Gender difference in clinical practice for cancer patients].
Y. Motoo
Nihon rinsho. Japanese journal of clinical…
2015
Corpus ID: 44638288
Solid tumors are generally more detected in male than female patients, except for sexual organs. However, females are dominant in…
Expand
Review
2010
Review
2010
Survival improvement in patients (pts) with small cell lung cancer (SCLC): A historical comparison before and after amrubicin (AMR) approval in Japan.
S. Niho
,
K. Kubota
,
+4 authors
Y. Nishiwaki
2010
Corpus ID: 75294561
e18105 Background: AMR is a totally synthetic anthracycline and a potent topoisomerase II inhibitor. Recent phase II trials…
Expand
2008
2008
Randomized, phase II trial comparing amrubicin with topotecan in patients (pts) with previously treated small cell lung cancer (SCLC)
S. Sugawara
,
A. Inoue
,
+7 authors
T. Nukiwa
2008
Corpus ID: 78948845
8042 Background: Amrubicin (A), a new anthracycline agent, and topotecan (T) are both active for previously treated SCLC. No…
Expand
2008
2008
Phase I study of amrubicin and cisplatin in previously untreated patients with advanced non-small-cell lung cancer
N. Yoshimura
,
S. Kudoh
,
Tatsuo Kimura
,
S. Mitsuoka
,
T. Yana
,
K. Hirata
2008
Corpus ID: 78606967
19119 Background: Amrubicin, a totally synthetic 9-aminoanthracycline, is one of the most active new agents for non- small-cell…
Expand
2008
2008
A phase I study of amrubicin and carboplatin for previously untreated patients with extensive stage small-cell lung cancer
M. Fukuda
,
Yusuke Nakamura
,
+7 authors
S. Kohno
2008
Corpus ID: 53938018
19070 Background: Amrubicin (AMR) and cisplatin are active in the treatment of small cell lung cancer (SCLC), and carboplatin…
Expand
2008
2008
Enhanced anti-tumor effect of trastuzumab combined with less cardiotoxic anthracycline, amrubicin, in a HER2-positive human cancer xenograft in athymic mice
Y. Tokuda
,
S. Umemura
,
Yuki Saito
,
Yasuhiro Suzuki
2008
Corpus ID: 78936252
14641 Background: Trastuzumab extends survival when combined with doxorubicin to patients with HER2- positive metastatic breast…
Expand
2008
2008
Phase II study of irinotecan plus cisplatin followed by amrubicin in patients with extensive-stage small-cell lung cancer (WJTOG 0301)
Y. Iwamoto
,
Masashi Kobayashi
,
+7 authors
K. Nakagawa
2008
Corpus ID: 74494334
19039 Background: The combination chemotherapy of irinotecan (CPT-11), that is a topoisomerase (topo) I inhibitor, and cisplatin…
Expand
2007
2007
A phase I study of amrubicin (AMR) and irinotecan (CPT-11) in relapsed small cell lung cancer(SCLC)
M. Kawahara
,
A. Kubo
,
+4 authors
T. Mio
2007
Corpus ID: 74269241
13548 Background: AMR and CPT-11 have shown excellent activity in extensive small cell lung cancer (SCLC). The aim of this study…
Expand
2005
2005
A combination phase I study of amrubicin and irinotecan (CPT-11) in patients with lung cancer
T. Kurata
,
H. Kaneda
,
+5 authors
M. Fukuoka
2005
Corpus ID: 74390126
7332 Background: A synergistic effect between topo I and topo II inhibitors in vivo has been reported by several investigators…
Expand
2005
2005
Development of a novel anti-tumor drug 'amrubicin', a completely synthetic anthracycline
T. Noguchi
,
M. Hanada
,
T. Yamaoka
,
S. Morisada
,
S. Ichii
2005
Corpus ID: 53312687
Anthracycline derivatives such as doxorubicin (DXR), daunorubicin (DNR) and epirubicin have been widely used for a variety of…
Expand